公开(公告)号：EP3337784A1

公开(公告)日：2018-06-27

申请号：EP16837721.6

申请日：2016-08-17

申请人： Academia Sinica ,  Memorial Sloan Kettering Cancer Center

发明人： MOORE, Malcolm ,  SHIEH, Jae-Hung ,  SU, Tsann-Long ,  LEE, Te-Chang

IPC分类号： C07C275/42 ,  C07D215/42 ,  C07D219/08 ,  A61P35/02

CPC分类号： A61K31/17 ,  A61K45/06

摘要： Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.